Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results
2011 | 83 | 12 | 641-645

Article title

Assessment of Activity of an Adhesion Molecule CD134 and CD137 in Colorectal Cancer Patients


Title variants

Languages of publication



Epidemiological studies prove that incidence of colorectal cancer is increasing. The first line therapy of colorectal cancer is surgical resection of the primary tumor and elimination of regional and remote metastases.The aim of the study was to determine expression of adhesion molecules CD134 and CD137 in the peripheral blood in colorectal cancer patients, depending on clinical cancer stage, size and invasion of the tumor.Material and methods. The study enrolled 72 patients with primary colorectal adenocarcinoma. An average patient age was 64.55 years. Clinical tumor stage was assessed using two scales: Dukes: A and Astler-Coller scale. Expression of adhesion molecules was determined in the peripheral blood collected on the day of the procedure and 10 days after the procedure.Results. An average activity of CD134 molecules (12.66%) was significantly higher than that of CD137 (6.26%) (p<0.001). Clinical tumor stage was assessed on Dukes scale and was unrelated to CD134 activity, while activity of CD137 was related to clinical cancer stage.Conclusions. CD137 activity is directly proportional to colorectal cancer stage. Surgical resection of the tumor results in increased CD134 and CD137 expression. Long term studies, enrolling larger groups of patients, including their subdivision to colon and rectal cancer, are required to utilize CD134 and CD137 in immune therapy of colorectal cancer.









Physical description


1 - 12 - 2011
17 - 2 - 2012


  • 2nd Department of General and Gastroenterological Surgery, Medical University in Białystok
  • 2nd Department of General and Gastroenterological Surgery, Medical University in Białystok
  • 2nd Department of General and Gastroenterological Surgery, Medical University in Białystok
  • Department of Clinical Immunology, Medical University in Białystok
  • 2nd Department of General and Gastroenterological Surgery, Medical University in Białystok


  • Chen S- H, Pham-Nguyen KB, Marinet O et al.: Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Molecular Therapy 2000; 2(1): 39-46.
  • Mazollini G, Murillo O, Atorrasagasti C et al.: Immunotherapy and immunoescape in colorectal cancer. World J Gastroenterol 2007; 13(44): 5822-31.
  • Petty JK, He K, Corless CL et al.: Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am J Surg 2002; 183: 512-18.
  • Tebutt NC, Cattell E, Midgley R et al.: Systemic treatment of colorectal cancer. Eur J Cancer 2002; 38: 1000-15.[Crossref]
  • Marinet O, Ermekova V, Qiao JQ et al.: Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long-term remission of liver metastases in mouse model. J National Cancer Institute 2000; 92(11): 931-36.
  • Sanz L, Blanco B, Alvarez-Vallina L: Antibodies and gene therapy: teaching old ‘magic bullets’ new trics. Trends in immunology 2004; 25(2): 85-91.[Crossref]
  • Cragg MS, French RR, Glennie MJ: Signaling antibodies in cancer therapy. Cancer 1999; 11: 541-47.
  • Mayer-Kuckuk P, Banerjee D, Kemeny N et al.: Molecular therapies of colorectal cancer metastatic to the liver. Molecular Therapy 2002; 5(5): 492-500.[Crossref]
  • Pan P-Y, Zang Y, Weber K et al.: OX40 ligation enhances primary and memory cytotoxic L lymphocyte responses in an immunotherapy for hepatic colon metastases. Molecular Therapy 2002; 6(4): 528-36.[Crossref]
  • Ballestrero A, Boy D, Moran E et al.: Immunotherapy with dendritic cells for cancer. Advanced Drug Delivery Reviews 2008; 60: 173-83.[WoS][PubMed][Crossref]
  • Tirapu I, Arina A, Mazollini G et al.: Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with colon cancer with anti-CD-137 monoclonal antibodies and alloantigens. Int J Cancer 2004; 110: 51-60.
  • Mocellin S, Nitti D: Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines. Medicinal Research Reviews 2008; 28(3): 413-44.[Crossref][PubMed][WoS]
  • Weinberg AD, Rivera M-M, Prell R et al.: Engagement of the OX-40 receptor in vivo enhances antitumor immunity. The J Immunology 2000; 164: 2160-69.
  • Croft M: Costimulation of T cells by OX-40, 4-1BB, and CD27. Cytokine Growth Factor Rec 2003; 14: 265-73.[Crossref][WoS]
  • Dimberg J, Hugander A, Wagsater D: Expression of CD137 and CD137 ligand in colorectal cancer patients. Oncology Reports 2006; 15: 1197-1200.
  • Zhang N, Sadun RE, Arias RS et al.: Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clinical Cancer Research 2007; 13: 2758-67.[WoS]
  • Cepowicz D, Stasiak-Bermuta A, Zalewski B et al.: Assessment expresion of the adhesion molecules, CD134 and CD137, In patients with colorectal cancer by flow cytometry. Ann Acad Medicae Bialostocensis 2004; 49: suppl 1: 34-36.
  • Vonderheide RH, June CH: A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cells immunotherapy. Immunol Res 2003; 27: 341-56.[PubMed][Crossref]

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.